Abstract
After acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)—a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85 % of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004–2009. Identification of HZ- and PHN-cases was performed based on ‘International Statistical Classification of Diseases’ and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5 % of HZ-cases developed PHN. One HZ-case caused on average €210 and €376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of €1,123 (€1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at €182 million (€105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.
Similar content being viewed by others
References
Wutzler, P., Färber, I., Wagenpfeil, S., Bisanz, H., Tischer, A.: Seroprevalence of varicella-zoster virus in the German population. Vaccine 20(1–2), 121–124 (2001)
Breuer, J., Whitley, R.: Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl 2), 25–29 (2007)
Hope-Simpson, R.E.: The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9–20 (1965)
Wittek, M., Doerr, H.W., Allwinn, R.: Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 105(5), 334–338 (2010). doi:10.1007/s00063-010-1061-3
Schmader, K., Gnann Jr, J.W., Watson, C.P.: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197(Suppl 2), S207–S215 (2008). doi:10.1086/522152
Drolet, M., Brisson, M., Levin, M.J., Schmader, K.E., Oxman, M.N., Johnson, R.W., et al.: A prospective study of the herpes zoster severity of illness. Clin. J. Pain 26(8), 656–666 (2010). doi:10.1097/AJP.0b013e3181eef686
Opstelten, W., Eekhof, J., Neven, A.K., Verheij, T.: Treatment of herpes zoster. Can. Fam. Physician 54(3), 373–377 (2008)
Forbes, H., Thomas, S., Langan, S.: The epidemiology and prevention of herpes zoster. Curr. Dermatol. Rep. 1(1), 39–47 (2012). doi:10.1007/s13671-011-0004-4
Edmunds, W.J., Brisson, M., Rose, J.D.: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23–24), 3076–3090 (2001). doi: 10.1016/S0264-410X(01)00044-5
Hope-Simpson, R.E.: Postherpetic neuralgia. J. R. Coll. Gen. Pract. 25(157), 571–575 (1975)
Jericho, B.G.: Postherpetic neuralgia: a review. Internet J. Pain Symptom Control Palliat. Care 8(1) (2010). doi: 10.5580/124b
EMA: European Public Assessment Report (EPAR) for ZOSTAVAX summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf (2006). Accessed 18 March 2011
Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(22), 2271–2284 (2005). doi:10.1056/NEJMoa051016
Tseng, H.F., Smith, N., Harpaz, R., Bialek, S.R., Sy, L.S., Jacobsen, S.J.: Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305(2), 160–166 (2011). doi:10.1001/jama.2010.1983
Schmader, K.E., Levin, M.J., Gnann, J.W., McNeil, S.A., Vesikari, T., Betts, R.F., et al.: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin. Infect. Dis. (2012). doi:10.1093/cid/cir970
GlaxoSmithKline: Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177]. http://clinicaltrials.gov/ct2/show/NCT01165177?term=herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1 (2011). Accessed 10 December 2011
MoH: Gesetzliche Krankenversicherung Mitglieder, mitversicherte Angehörige und Krankenstand Monatswerte Januar bis February 2012. http://bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_Januar-Februar_2012.pdf (2012). 15 October 2012
Ihle, P., Köster, I., Herholz, H., Rambow-Bertram, P., Schardt, T., Schubert, I.: Versichertenstichprobe AOK Hessen/KV Hessen—Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der Gesetzlichen Krankenversicherung. Das Gesundheitswesen 67, 638–645 (2005). doi:10.1055/s-2005-858598
Swart, E., Ihle, P., Geyer, S., Grobe, T., Hofmann, W.: GPS—good practice secondary data analysis. Working group for the survey and utilization of secondary data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP). Gesundheitswesen 67(06), 416–421 (2005)
Annemans, L., Bresse, X., Gobbo, C., Papageorgiou, M.: Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J. Med. Econ. 13(3), 537–551 (2010)
WHO: List of ICD-10 classifications. http://apps.who.int/classifications/apps/icd/icd10online/ (2007). Accessed 30 November 2011
Ultsch, B., Siedler, A., Rieck, T., Reinhold, T., Krause, G., Wichmann, O.: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect. Dis. 11(1), 173 (2011)
Gross, G., Schofer, H., Wassilew, S., Friese, K., Timm, A., Guthoff, R.et al.: Herpes zoster guideline of the German Dermatology Society (DDG). J. Clin. Virol. 26(3), 277–289; discussion 291–273 (2003). doi:10.1016/S1386-6532(03)00005-2
Brisson, M.: Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can. J. Public Health 99(5), 383–386 (2008)
Gauthier, A., Breuer, J., Carrington, D., Martin, M., Remy, V.: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect. 137(1), 38–47 (2009). doi:10.1017/S0950268808000678
Gonzalez Chiappe, S., Sarazin, M., Turbelin, C., Lasserre, A., Pelat, C., Bonmarin, I., et al.: Herpes zoster: burden of disease in France. Vaccine 28(50), 7933–7938 (2010)
Max, M., Schafer, S., Culnane, M., Smoller, B., Dubner, R., Gracely, R.: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 38(9), 1427 (1988)
Opstelten, W., Mauritz, J.W., de Wit, N.J., van Wijck, A.J., Stalman, W.A., van Essen, G.A.: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam. Pract. 19(5), 471–475 (2002)
van Hoek, A.J., Gay, N., Melegaro, A., Opstelten, W., Edmunds, W.J.: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454–1467 (2009). doi:10.1016/j.vaccine.2008.12.024
Dworkin, R.H., Portenoy, R.K.: Pain and its persistence in herpes zoster. Pain 67(2–3), 241–251 (1996)
Yawn, B.P.: Post-shingles neuralgia by any definition is painful, but is it PHN? Mayo Clin. Proc. 86(12), 1141–1142 (2011). doi:10.4065/mcp.2011.0724
Schreyogg, J., Tiemann, O., Busse, R.: Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system? Health Care Manag. Sci. 9(3), 269–279 (2006)
IQWiG: Cost estimation—working paper, Version 1.0. https://www.iqwig.de/download/Working_Paper_Cost_Estimation.pdf (2009). Accessed 22 November 2011
DESTATIS: Lohnnebenkosten im Verhältnis zu den Bruttolöhnen und -gehältern im Jahr 2010. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Presse/pm/2011/04/PD11__143__624,templateId=renderPrint.psml (2011). Accessed 6 February 2012
Krauth, C., Hessel, F., Hansmeier, T., Wasem, J., Seitz, R., Schweikert, B.: Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67(10), 736–746 (2005). doi:10.1055/s-2005-858698
DESTATIS: Verdienste und Arbeitskosten—Verdienststrukturerhebung 2006, Verdienste nach Berufen (2009). https://www.destatis.de/DE/Publikationen/Thematisch/VerdiensteArbeitskosten/VerdiensteBerufe/VerdienstenachBerufe5621108069004.pdf?__blob=publicationFile. Accessed 6 Mar 2012
DiCiccio, T.J., Efron, B.: Bootstrap confidence intervals. Stat. Sci. 11(3), 189–228 (1996)
DESTATIS: Bevölkerung und Erwerbstätigkeit—Bevölkerungsfortschreibung (2010). https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsstand/Bevoelkerungsfortschreibung2010130107004.pdf?__blob=publicationFile. Accessed 6 Mar 2012
DESTATIS: Consumer price overall index (2011). http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/EN/Content/Statistics/TimeSeries/EconomicIndicators/BasicData/Content100/vpi102a.psml. Accessed 8 Dec 2011
Welte, R., Feenstra, T., Jager, H., Leidl, R.: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22(13), 857–876 (2004). doi:10.2165/00019053-200422130-00004
OECD: Country statistical profiles. http://www.oecd.org/country/ (2011). Accessed 18 Jan 2012
Paul, E., Thiel, T.: Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 47(8), 604–609 (1996)
Schiffner-Rohe, J., Jow, S., Lilie, H.M., Köster, I., Schubert, I.: Herpes zoster in Deutschland—Eine retrospektive analyse von GKV-Daten. MMW Fortschr. Med. Orig. IV/2009(151), 193–197 (2009)
Gialloreti, L., Merito, M., Pezzotti, P., Naldi, L., Gatti, A., Beillat, M., et al.: : Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect. Dis. 10(1), 230 (2010)
Donahue, J.G., Choo, P.W., Manson, J.E., Platt, R.: The incidence of herpes zoster. Arch. Intern. Med. 155(15), 1605–1609 (1995)
Cebrian-Cuenca, A., Diez-Domingo, J., San-Martin-Rodriguez, M., Puig-Barbera, J., Navarro-Perez, J.: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian Community of Spain. BMC Infect. Dis. 11(1), 302 (2011)
Pierik, J., Gumbs, P., Fortanier, S., Van Steenwijk, P., Postma, M.: Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect. Dis. 12(1), 110 (2012)
Insinga, R.P., Itzler, R.F., Pellissier, J.M., Saddier, P., Nikas, A.A.: The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20(8), 748–753 (2005). doi:10.1111/j.1525-1497.2005.0150.x
Leung, J., Harpaz, R., Molinari, N.-A., Jumaan, A., Zhou, F.: Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis. 52(3), 332–340 (2011). doi:10.1093/cid/ciq077
Tanuseputro, P., Zagorski, B., Chan, K.J., Kwong, J.C.: Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29(47), 8580–8584 (2011). doi:10.1016/j.vaccine.2011.09.024
Yawn, B.P., Saddier, P., Wollan, P.C., St Sauver, J.L., Kurland, M.J., Sy, L.S.: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 82(11), 1341–1349 (2007)
Schmader, K.E.: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18(6), 350–354 (2002)
Stein, A.N., Britt, H., Harrison, C., Conway, E.L., Cunningham, A., Macintyre, C.R.: Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27(4), 520–529 (2009). doi:10.1016/j.vaccine.2008.11.012
Schiffner-Rohe, J., Köster, I., Beillat, M., Lilie, H.M., Schubert, I.: Ressourcenverbrauch und Kosten von Herpes zoster und postherpetischer Neuralgie in Deutschland. Gesundh. Ökon. Qual. Manag.(EFirst) (2010). doi:10.1055/s-0029-1245896
MacIntyre, C.R., Chu, C.P., Burgess, M.A.: Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol. Infect. 131(1), 675–682 (2003)
Scott, F.T., Johnson, R.W., Leedham-Green, M., Davies, E., Edmunds, W.J., Breuer, J.: The burden of Herpes Zoster: a prospective population based study. Vaccine 24(9), 1308–1314 (2006). doi:10.1016/j.vaccine.2005.09.026
Insinga, R.P., Itzler, R.F., Pellissier, J.M.: Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 25(2), 155–169. doi: 10.1111/j.1525-1497.2005.0150.x (2007)
Hoffmann, F., Icks, A.: Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen (EFirst) (2011). doi:10.1055/s-0031-1275711
Hoffmann, F., Icks, A.: Diabetes prevalence based on health insurance claims: large differences between companies. Diabet. Med. 28(8), 919–923 (2011). doi:10.1111/j.1464-5491.2011.03305.x
Damm, K., Lange, A., Zeidler, J., Braun, S., Graf von der Schulenburg, J.M.: Einführung des neuen Tätigkeitsschlüssels und seine Anwendung in GKV-Routinedatenauswertungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55(2), 238–244 (2012). doi:10.1007/s00103-011-1418-7
Zoike, E., Bödeker, W.: Berufliche Tätigkeit und Arbeitsunfähigkeit. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51(10), 1155–1163 (2008). doi:10.1007/s00103-008-0650-2
Krauth, C.: Methoden der Kostenbestimmung in der gesundheitsökonomischen Evaluation. Gesundh. Ökon. Qual. Manag. 15(05), 251–259 (2010). doi:10.1055/s-0029-1245680
Greiner, W.: 4. Die Berechnung von Kosten und Nutzen. In: Schöffski, O., Graf von der Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluation, vol. 3. Springer, Heidelberg (2008)
Luce, B.R., Manning, W.G., Siegel, J.E., Lipscomb, J.: Estimating costs in cost-effectiveness analysis. In: Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C. (eds.) Cost-Effectiveness in health and medicine. Oxford University Press, New York (1996)
Acknowledgements
The authors gratefully acknowledge the supporting consultancy of Dr. Andrej Rasch [Federal Joint Committee (G-BA)]. Furthermore, we would like to thank AOK Hesse, KV Hesse, and the Ministry of Social Affairs Hesse for the permission to access data. Funding for this study was provided fully by the Robert Koch Institute (FKZ 1362/1-983).
Conflict of interest
Before initiation of this research, B.U. was an employee of Sanofi Pasteur MSD (provider of a herpes zoster vaccine) from April 2008 to May 2010. I.K. and I.S. conducted a research project in 2007 that was fully funded by Sanofi Pasteur MSD. (provider of a herpes zoster vaccine).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ultsch, B., Köster, I., Reinhold, T. et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 14, 1015–1026 (2013). https://doi.org/10.1007/s10198-012-0452-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-012-0452-1